Our Mission

Using open source principles, and by nurturing a movement, we seek to create affordable new medicines in areas of great health need

about ospf

support our work

Photo from The New York Times

The New York Times

​Why a Century-Old Vaccine Offers New Hope Against Pathogens

The century-old BCG tuberculosis vaccine, accessible to billions, trusted by billions, and which costs only 15 cents a dose, shows 92% efficacy against COVID-19 in very small clinical trial by Professor Denise Faustman of Harvard Medical School.  It is thought that the vaccine boosts the overall immune system. This exemplifies OSPF's 2+ year exploration of certain off patent vaccines, including BCG, against COVID-19, future pandemics and other diseases - a new scientific and legal/economic paradigm for vaccines. We cannot guarantee that they will work, but we absolutely must explore them. The New York Times article mentions OSPF. "“Imagine if we could use existing vaccines to curb pandemics — that would change world history,” Mr. Menon said."

Read Full Article HERE

Newsweek profiles OSPF as one of its "50 Greatest Disruptors: Visionaries and Innovators Who Are Changing the World"

Learn More

Image from www.newsweek.com

The New Yorker features OSPF's universal open source vaccine work and approach

Beyond the Booster Shot: Could a “broad spectrum” booster increase our immunity to many pathogens simultaneously?

-Matthew Hutson, The New Yorker

Read article

Illustration by Nicholas Konrad / The New Yorker from www.newyorker.com

VACCINUUM
​Universally Available, Ultra-Broad Spectrum Vaccines

Toward Universal Vaccines/ A Protective Layer for Humanity: Ultra-Broad Spectrum Open Source Vaccines to Protect Against SARS-CoV-2 Variants, Other Diseases, and Future Epidemics - Phase 3 Trials and Other Explorations

Learn More About this Project

Neglected/Infectious Disease Knowledge Graphs

Open Source Pharma Foundation and Ingentium are collaborating on the implementation of an open information commons for the collaborative development of new disease treatments using an open source methodology, initially focusing on tuberculosis, Chikungunya, and Nipah virus.

visit OSPF-Ingentium applications

FastCompany World Changing Ideas Awards 2020: ​AI and Data Finalists and Honorable Mentions

Open Source Pharma Foundation receives honorable mention for its work harnessing the power of data, machine learning, or artificial intelligence to understand the world and empower change

View World Changing Ideas Awards 2020

Read from Fast Company: "How open-source medicine could prepare us for the next pandemic"

SUPPORT OUR WORK IN INDIA, USA, AND AROUND THE WORLD

Donate

PHASE 3 OPEN SOURCE COVID-19 VACCINE CLINICAL TRIAL
​

OSPF is a collaborator in a Phase 3 COVID-19 vaccine trial in Brazil, testing the efficacy of the off-patent MMR vaccine and of the low-cost influenza vaccine against the Gamma SARS-CoV-2 variant. The trial has commenced, with 6000 participants across three arms.  Co-PI’s Prof. Mihai Netea, Radboud University, Netherlands, and Prof. Sergio Henrique Nascente Costa, Federal University of Goias. Brazil. Protocol summary here.

view Protocol summary

By HelloScience
Village Lab

Meet Dr. UC Jaleel, Principal Scientist - Cheminformatics of OSPF in India.  From a small school in rural India to creating a Village Lab that does computational drug discovery, see how he is contributing to the new era of collaboration, and building a community-driven mode of capacity-building and research.

view online

More videos from HelloScience

Short Teaser
Medicine For All

​Jaykumar Menon, Co-Founder and Chair of Open Source Pharma Foundation, shares why we need an alternative pharmaceutical system and how OSPF is working to revolutionize the pharma industry. See clips taken at the 3rd Open Source Pharma  Conference (OSP3) in Paris!

view online

March 24, 2019
World Tuberculosis Day

The 3rd Global Open Source Pharma Conference (OSP3) took place in Paris in March 2019. This video was put together at the conference to commemorate World Tuberculosis Day. Have a look!

View online

"I call on all countries, companies, and research institutions to support open data, open science, and open collaboration so all people can enjoy the benefits of science and research."

-Dr. Tedros Ghebreyesus, Director General of the World Health Organization (WHO)

view More by @billGates

In partnership with the National Institute for Research in Tuberculosis in India, we have commenced phase 2b clinical trials

learn more about the clinical trials

OSPF is a proud supporter of the Open Source Pharma movement

OSP3 - Paris - March 2019

OSPF took part in the third conference for the open source pharma movement that was held between March 21st and 23rd, 2019 at the Center for Research and Interdisciplinarity (CRI) in Paris. For more information, visit the Open Source Pharma community website.

Visit site

​PRESS

Fast Company
How open-source medicine could prepare us for the next pandemic

read article

BBC News
'We should own our own livelihood and our own dream'

Read Article

The Lancet
Can open-source drug development deliver?

Read article

See more news articles

Discovering the Person Who Will Discover the Molecule

​Education for Grand Challenges -
​Community-Based TB Drug Discovery

HISTORY OF OSPF
MEET OUR TEAM
MAKE A DONATION

Back To Top